Pfizer's new migraine drug has been approved for market launch. Lilly and Novartis Same Target Injection have been approved successively
终究未留
发表于 2024-1-26 20:03:07
1280
0
0
Today (January 26th), Pfizer announced that its new generation of specific migraine treatment drug, Rimezepam orally disintegrating tablets, has been approved by the National Medical Products Administration (NMPA) of China for the acute treatment of migraines in adults with or without aura.
Pfizer's official WeChat official account
According to a Pfizer press release, this is a calcitonin gene related peptide (CGRP) receptor antagonist that uses orally disintegrating tablet technology. It can block key pathways related to the onset of migraine, quickly and continuously relieve headaches and related accompanying symptoms. It is easy to take and has no contraindications to cardiovascular diseases.
Rimezepam orally disintegrating tablets are the first oral CGRP receptor antagonist to show positive results in a key trial in China. In this study, patients achieved the common primary endpoint of pain and most troubled symptom relief after a single oral dose of 75mg of medication for 2 hours. Patients can quickly relieve pain and eliminate the most troublesome symptoms within 45 minutes, restore normal function within 60 minutes, and eliminate pain within 90 minutes; For most patients, its sustained therapeutic effect can reach 48 hours.
Remazepam sulfate orally disintegrating tablets were approved for marketing by the US FDA in 2020 for the acute treatment of adult migraine attacks. In May 2022, Pfizer acquired Biohaven for approximately $11.6 billion to expand its migraine product pipeline, thereby acquiring this product.
Migraine is a common chronic disease. The World Health Organization (WHO) lists migraine as one of the top 10 most disabling internal medicine diseases. A reporter from the Daily Economic News noticed that the orally disintegrating tablets of remizepam sulfate are not the only new migraine medication recently launched.
On the 9th of this month, Lilly Galcanezumab injection was approved for sale in China to prevent adult onset migraines.
Galcanezumab is a fully human monoclonal antibody developed by Eli Lilly targeting calcitonin gene related peptide (CGRP), which has been recognized as a breakthrough therapy by the FDA. CGRP is an effective vasodilator neuropeptide, whose release levels significantly increase during migraine attacks. Inhibiting the activity of CGRP and its receptor (CGRPR) can alleviate headaches and prevent migraine attacks.
As of November 2023, a total of 8 migraine drugs targeting CGRP have been approved for marketing worldwide, including Remdesipam Sulfate orally disintegrating tablets and Lilly Galcanezumab. Among them, Anjin& Novartis Pharmaceuticals also approved the marketing of its Irenazumab in September last year by the National Medical Products Administration. It is the first fully human monoclonal antibody drug approved in China that targets the calcitonin gene related peptide (CGRP) receptor, requiring monthly injections to prevent adult migraines.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Pfizer will make an appearance at the 7th CIIE and make a commitment to its development for the next five years
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
- Exhibits become commodities in seconds! Prostate cancer new drug approved in China, Pfizer Wang Yu: promoting China's new drug market to synchronize with the global market
- Exploring the CIIE | New products from Sinogen, Roche, and Pfizer become highlights of the CIIE
- Pfizer plans to sell hospital drug division, company responds
- After closing factories and laying off employees, Pfizer is reportedly considering selling its hospital drug division
- Pfizer and CR Pharma reach strategic partnership on four mature drugs
- Multiple new indications for Merck drugs approved for market in China
- Pfizer expects revenue of $61 billion to $64 billion in 2025, with an estimated $63.23 billion
-
隔夜株式市場 世界の主要指数は金曜日に多くが下落し、最新のインフレデータが減速の兆しを示したおかげで、米株3大指数は大幅に回復し、いずれも1%超上昇した。 金曜日に発表されたデータによると、米国の11月のPC ...
- SNT
- 前天 12:48
- 支持
- 反对
- 回复
- 收藏
-
長年にわたって、昔の消金大手の捷信消金の再編がようやく地に着いた。 天津銀行の発表によると、同行は京東傘下の2社、対外貿易信託などと捷信消金再編に参加する。再編が完了すると、京東の持ち株比率は65%に達し ...
- SNT
- 前天 12:09
- 支持
- 反对
- 回复
- 收藏
-
【GPT-5屋台で大きな問題:数億ドルを燃やした後、OpenAIは牛が吹くのが早いことを発見した】OpenAIのGPT-5プロジェクト(Orion)はすでに18カ月を超える準備をしており、関係者によると、このプロジェクトは現在進 ...
- SNT
- 4 小时前
- 支持
- 反对
- 回复
- 收藏
-
【ビットコインが飛び込む!32万人超の爆倉】データによると、過去24時間で世界には32万7000人以上の爆倉があり、爆倉の総額は10億ドルを超えた。
- 断翅小蝶腥
- 3 天前
- 支持
- 反对
- 回复
- 收藏